Journal of Neuro-Oncology

, Volume 110, Issue 3, pp 369–374 | Cite as

Abbreviated course of radiation therapy with concurrent temozolomide for high-grade glioma in patients of advanced age or poor functional status

  • Marsha Reyngold
  • Andrew B. Lassman
  • Timothy A. Chan
  • Yoshiya Yamada
  • Philip H. Gutin
  • Kathryn Beal
Clinical Study

Abstract

Elderly or frail patients with high-grade gliomas (HGG) can be effectively treated with an abbreviated course of radiation therapy (RT) consisting of 40 Gy in 15 fractions. Concurrent temozolomide (TMZ) improves survival in non-elderly patients with glioblastoma treated with standard schedule of 60 Gy in 30 fractions. We describe our institutional experience of combining abbreviated RT with concurrent TMZ for treatment of HGG. Between 1/1/2004 and 2/5/2010 31 patients were treated. Survival was estimated with the Kaplan–Meier method. Toxicity was scored according to CTCAE 3.0. Median age was 66 years (range 32–90), and 17 patients had Karnofsky performance score <70. At the time of analysis, 30 patients (98 %) had died, with a followup of 14 months in the surviving patient. Median survival was 11 months (range 1–20), and 41 % of patients were alive at 12 months. Thirty patients (97 %) had a decreased corticosteroid requirement after completion of therapy. Only one new hospitalization for worsening neurologic status was required during therapy. Grade 3–4 hematologic toxicity occurred in 11 patients. Abbreviated RT with concurrent TMZ provides a clinical benefit, is safe and tolerable in patients of advanced age or poor functional status.

Keywords

High-grade glioma Glioblastoma Abbreviated radiotherapy Temozolomide 

Notes

Acknowledgments

We would like to thank Eve Ferdman for her help with manuscript preparation.

Conflicts of interest

Marsha Reyngold: none; Andrew B. Lassman: Consultant/Advisory role for Bristol-Myers, Squibb, Eisai, Enzon, Genentech, Imclone, Schering-Plough, Sigma Tau, Honoraria-Genentech, Schering-Plough, Research funding-AstraZeneca, Genentech, Keryx, Schering- Plough, Sigma Tau; Timothy A. Chan: none; Yoshiya Yamada: Consultant/Advisory role for American Brachytherapy Society, Varian Medical Systems; Honoraria: Institute of Medical Education; Philip Gutin: none; Kathryn Beal: none.

References

  1. 1.
    Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE et al (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704–710PubMedCrossRefGoogle Scholar
  2. 2.
    Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R (2006) Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24:2563–2569PubMedCrossRefGoogle Scholar
  3. 3.
    Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Owens G, Ransohoff J II, Robertson JT, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323–1329PubMedCrossRefGoogle Scholar
  4. 4.
    Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, Guillamo JS, Jadaud E, Colin P, Bondiau PY, Menei P, Loiseau H, Bernier V, Honnorat J, Barrie M, Mokhtari K, Mazeron JJ, Bissery A, Delattre JY (2007) Radiotherapy for glioblastoma in the elderly. N Engl J Med 356:1527–1535PubMedCrossRefGoogle Scholar
  5. 5.
    Slotman BJ, Kralendonk JH, van Alphen HA, Kamphorst W, Karim AB (1996) Hypofractionated radiation therapy in patients with glioblastoma multiforme: results of treatment and impact of prognostic factors. Int J Radiat Oncol Biol Phys 34:895–898PubMedCrossRefGoogle Scholar
  6. 6.
    Jeremic B, Shibamoto Y, Grujicic D, Milicic B, Stojanovic M, Nikolic N, Dagovic A, Aleksandrovic J (1999) Short-course radiotherapy in elderly and frail patients with glioblastoma multiforme. A phase II study. J Neurooncol 44:85–90PubMedCrossRefGoogle Scholar
  7. 7.
    Idbaih A, Taillibert S, Simon JM, Psimaras D, Schneble HM, Lopez S, Lang P, Toubiana T, Feuvret L, Delattre JY, Mazeron JJ (2008) Short course of radiation therapy in elderly patients with glioblastoma multiforme. Cancer Radiother 12:788–792PubMedCrossRefGoogle Scholar
  8. 8.
    Bauman GS, Gaspar LE, Fisher BJ, Halperin EC, Macdonald DR, Cairncross JG (1994) A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme. Int J Radiat Oncol Biol Phys 29:835–839PubMedCrossRefGoogle Scholar
  9. 9.
    Roa W, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, Fisher B, Fulton D, Gulavita S, Hao C, Husain S, Murtha A, Petruk K, Stewart D, Tai P, Urtasun R, Cairncross JG, Forsyth P (2004) Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22:1583–1588PubMedCrossRefGoogle Scholar
  10. 10.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRefGoogle Scholar
  11. 11.
    Chinot OL, Barrie M, Frauger E, Dufour H, Figarella-Branger D, Palmari J, Braguer D, Hoang-Xuan K, Moktari K, Peragut JC, Martin PM, Grisoli F (2004) Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 100:2208–2214PubMedCrossRefGoogle Scholar
  12. 12.
    Glantz M, Chamberlain M, Liu Q, Litofsky NS, Recht LD (2003) Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 97:2262–2266PubMedCrossRefGoogle Scholar
  13. 13.
    Brandes AA, Vastola F, Basso U, Berti F, Pinna G, Rotilio A, Gardiman M, Scienza R, Monfardini S, Ermani M (2003) A prospective study on glioblastoma in the elderly. Cancer 97:657–662PubMedCrossRefGoogle Scholar
  14. 14.
    Laperriere N OCC, Ding K (2008) Rationale and design for a phase III randomized controlled trial in elderly patients with glioblastoma multiforme. NCIC CTG CE 6 13th Biannual Canadian Neuro-Oncology MeetingGoogle Scholar
  15. 15.
    Combs SE, Wagner J, Bischof M, Welzel T, Wagner F, Debus J, Schulz-Ertner D (2008) Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int J Radiat Oncol Biol Phys 70:987–992PubMedCrossRefGoogle Scholar
  16. 16.
    Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V, Bacci A, Agati R, Calbucci F, Ermani M (2009) Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 115:3512–3518PubMedCrossRefGoogle Scholar
  17. 17.
    Minniti G, De Sanctis V, Muni R, Filippone F, Bozzao A, Valeriani M, Osti MF, De Paula U, Lanzetta G, Tombolini V, Maurizi Enrici R (2008) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol 88:97–103PubMedCrossRefGoogle Scholar
  18. 18.
    Gerstein J, Franz K, Steinbach JP, Seifert V, Fraunholz I, Weiss C, Rodel C (2010) Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma. Radiother Oncol 97:382–386PubMedCrossRefGoogle Scholar
  19. 19.
    Minniti G, Lanzetta G, Scaringi C, Caporello P, Salvati M, Arcella A, De Sanctis V, Giangaspero F, Enrici RM (2012) Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys 83:93–99PubMedCrossRefGoogle Scholar
  20. 20.
    Cao JQ, Fisher BJ, Bauman GS, Megyesi JF, Watling CJ, Macdonald DR (2012) Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience. J Neurooncol 107(2):395–405PubMedCrossRefGoogle Scholar
  21. 21.
    Sijben AE, McIntyre JB, Roldan GB, Easaw JC, Yan E, Forsyth PA, Parney IF, Magliocco AM, Bernsen H, Cairncross JG (2008) Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. J Neurooncol 89:97–103PubMedCrossRefGoogle Scholar
  22. 22.
    Fiorica F, Berretta M, Colosimo C, Stefanelli A, Ursino S, Zanet E, Palmucci T, Maugeri D, Malaguarnera M, Palmucci S, Grasso M, Tirelli U, Cartei F (2010) Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with concomitant temozolomide. Arch Gerontol Geriatr 51: 31–35Google Scholar
  23. 23.
    Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13: 707–715Google Scholar
  24. 24.
    Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916–926PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2012

Authors and Affiliations

  • Marsha Reyngold
    • 1
  • Andrew B. Lassman
    • 2
  • Timothy A. Chan
    • 1
  • Yoshiya Yamada
    • 1
  • Philip H. Gutin
    • 3
  • Kathryn Beal
    • 1
  1. 1.Department of Radiation OncologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Department of NeurologyColumbia University Medical CenterNew YorkUSA
  3. 3.Department of NeurosurgeryMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations